Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

748 results about "Isoleucine" patented technology

Isoleucine (symbol Ile or I) is an α-amino acid that is used in the biosynthesis of proteins. It contains an α-amino group (which is in the protonated −NH⁺₃ form under biological conditions), an α-carboxylic acid group (which is in the deprotonated −COO⁻ form under biological conditions), and a hydrocarbon side chain with a branch (a central carbon atom bound to three other carbon atoms). It is classified as a non-polar, uncharged (at physiological pH), branched-chain, aliphatic amino acid. It is essential in humans, meaning the body cannot synthesize it, and must be ingested in our diet. Isoleucine is synthesized from pyruvate employing leucine biosynthesis enzymes in other organisms such as bacteria. It is encoded by the codons AUU, AUC, and AUA.

Ketoalkyd reductoisomerase mutant, genetically engineered bacterium for high yield of D-pantothenic acid and application of genetically engineered bacterium

The invention provides a keto-alcohol acid reductoisomerase mutant and application of the keto-alcohol acid reductoisomerase mutant in construction of genetically engineered bacteria for high yield of D-pantothenic acid. In order to solve the technical problem that in the prior art, the yield of D-pantothenic acid synthesized through microbial fermentation is not high, semi-rational design of enzyme is adopted, and a keto-alcohol acid reductoisomerase mutant with substrate specificity is obtained and applied to construction of genetically engineered bacteria for high yield of D-pantothenic acid. According to the invention, a genetically engineered bacterium with high yield of D-pantothenic acid is constructed by utilizing the keto-alcohol acid reductoisomerase mutant through a CRISPR-Cas9 gene editing technology, so that the yield of D-pantothenic acid is increased by about 12.04%, and compared with an original strain, the valine accumulation amount in obtained fermentation liquor is almost unchanged compared with that of a control, and the yield of D-pantothenic acid is greatly improved. However, the accumulation of branched chain amino acid isoleucine is less, so that the modification of the substrate specificity of the keto-alcohol acid reductoisomerase is achieved.
Owner:ZHEJIANG UNIV OF TECH

Esterase mutant for degrading ethyl carbamate and application thereof

ActiveCN120118877ABacteriaHydrolasesA-siteCarbamic acid ethyl ester
The invention relates to the technical field of gene engineering and enzyme engineering, in particular to an esterase mutant for degrading ethyl carbamate and application of the esterase mutant, the esterase mutant has an amino acid sequence as shown in SEQ ID NO.1 which is subjected to site mutation, the site mutation is any one or more site combined mutation of V129S, V161L or I229M, and the amino acid sequence of the esterase mutant is shown in SEQ ID NO.1. The V129S site mutation is that valine at the 129 site is mutated into serine, the V161L site mutation is that valine at the 161 site is mutated into leucine, and the I229M site mutation is that isoleucine at the 229 site is mutated into methionine. Mutation is carried out through a site-directed mutagenesis method, so that the amino acid sequence of the esterase mutant V129S / I229M is changed, the autoplasmic structure and function of eggs are changed, the esterase mutant V129S / I229M with the ethyl carbamate hydrolysis rate increased to 6.55 times in an acid environment is finally obtained, and the esterase mutant V129S / I229M has high industrial application value.
Owner:ANHUI POLYTECHNIC UNIV

Culture solution and culture method for ganoderma lucidum

The invention discloses a ganoderma lucidum culture solution and a culture method thereof. Comprising the following raw materials in parts: 30-40 parts of water, 10-20 parts of corn flour, 1-5 parts of ammonium nitrate, 1-5 parts of monopotassium phosphate, 1-5 parts of potassium sulfate, 1-5 parts of boric acid, 1-5 parts of manganese sulfate, 1-5 parts of zinc sulfate, 1-5 parts of copper sulfate, 1-5 parts of ferric sulfate, 1-5 parts of a short-acting growth regulator, 1-5 parts of amino acid, 1-5 parts of vitamins, 1-5 parts of a seaweed extract, 1-5 parts of honey and 1-5 parts of peaches and oranges. The short-acting growth regulator is prepared from gibberellin, auxin and cytokinin according to the ratio of (2-5): (1-8): (2-9), and the amino acid is prepared by mixing isoleucine, lysine, methionine and phenylalanine according to the ratio of (1-5): (2-8): (4-9): (5-7). The nutrient purity of the culture solution can be greatly increased, the fatality rate is reduced, cell elongation and rooting are promoted, plant metabolism and growth can be greatly promoted, and the quality of ganoderma lucidum is improved.
Owner:任海博

Immunoglobulin variable domains

VH domain, in which: (i) the amino acid residue at position 1 12 is one of K or Q; and / or (ii) the amino acid residue at position 89 is T; and / or (iii) the amino acid residue at position 89 is L and the amino acid residue at position 1 10 is one of K or Q; and (iv) in each of cases (i) to (hi), the amino acid at position 1 1 is preferably V; and in which said VH domain contains a C-terminal extension (X)n, in which n is 1 to 10, preferably 1 to 5, such as 1, 2, 3, 4 or 5 (and preferably 1 or 2, such as 1); and each X is an (preferably naturally occurring) amino acid residue that is independently chosen, and preferably independently chosen from the group consisting of alanine (A), glycine (G), valine (V), leucine (L) or isoleucine (I).
Owner:SANOFI SA(FR)

Low-toxicity broad-spectrum antibacterial peptide with WW as symmetric center and application thereof

The invention discloses application of a low-toxicity broad-spectrum antibacterial peptide taking WW as a symmetric center, WK is repeated twice and symmetrically distributed on two sides, WW is taken as the symmetric center to obtain an antibacterial peptide WKWKWWKWKW-NH2 (N2W2), and tryptophan at the C terminal and the N terminal of the N2W2 is replaced with leucine and / or isoleucine to obtain the antibacterial peptide. The antibacterial peptide can basically maintain the excellent antibacterial activity of the parent peptide, and the hemolytic activity of the antibacterial peptide is greatly reduced, so that the safety is improved. Wherein the antibacterial activity of IL-N2W2 is the highest, but the stability of IL-N2W2 needs to be improved, so that D-IL-N2W2 is obtained by carrying out D-type amino acid substitution on IL-N2W2. The D-IL-N2W2 keeps the high antibacterial activity and low toxicity of IL-N2W2, can still completely inhibit the growth of bacteria after being incubated with high-concentration trypsin or chymotrypsin, has great potential in the aspect of relieving the drug resistance of antibiotics, and has good application prospects in preparation of clinical antibacterial drugs.
Owner:LANZHOU UNIV

Fluorescent protein selection marker staygold-ynaMr gene and application thereof

The invention provides a fluorescent protein selection marker staygold-ynaMr gene and application thereof, and belongs to the technical field of biological engineering. The method comprises the following steps: replacing codons of L-isoleucine in nucleotide sequences of a fluorescent protein gene staygold and a gene ynaM by using a rare codon ATA to respectively obtain the fluorescent protein gene staygold after codon replacement and the gene ynaMr after codon replacement, and connecting the two segments of genes after codon replacement by using a flexible protein peptide, and the fluorescent protein selection marker staygold-ynaMr gene is obtained. Experiments prove that the gene can obviously improve the screening efficiency of L-isoleucine high-yield strains.
Owner:ZHUCHENG DONGXIAO BIOTECH CO LTD +1

High-activity TET dioxygenase mutant as well as construction method and application thereof

The invention discloses a high-activity TET dioxygenase mutant as well as a construction method and application thereof. The TET dioxygenase mutant is obtained from an amino acid sequence of wild type TET dioxygenase as shown in SEQ ID NO.1 according to any one of the following mutation modes: a, the 150th proline is mutated into alanine; and b, proline at the 150th site is mutated into alanine, and isoleucine at the 235th site is mutated into methionine. The TET dioxygenase mutant provided by the invention can be stabilized in an escherichia coli system, the purification effect is good, the preparation difficulty is reduced, and the activity is remarkably improved compared with that of a wild type. The methylation gene transformation effect is far better than that of a traditional bisulfite transformation method, and the method has a good application prospect.
Owner:SUZHOU HAIMIAO BIOTECH CO LTD

Polygonatum sibiricum and saussurea involucrate bone marrow peptide tablet as well

The invention relates to the technical field of functional product preparation, and provides a rhizoma polygonati and saussurea involucrata bone marrow peptide tablet as well as a preparation method and application thereof. The rhizoma polygonati and saussurea involucrata bone marrow peptide tablet is prepared from the following components: collagen peptide powder, L-isoleucine, a compound nutrient supplement, rhizoma polygonati, sorbitol, yak bone marrow peptide powder, fructus phyllanthi, fructus alpiniae oxyphyllae, mulberry powder, a saussurea involucrata culture and magnesium stearate. All the components of the rhizoma polygonati and saussurea involucrata bone marrow peptide tablet disclosed by the invention have a synergistic effect, so that the effects of conditioning sub-health, maintaining joints and assisting in treating diseases can be achieved.
Owner:SHIJIAZHUANG ZANGNUO BIOTECH

Branched chain amino acid transaminase gene and application thereof

The invention provides a branched chain amino acid transaminase gene and application thereof, and belongs to the field of gene engineering. According to the invention, the branched chain amino acid transaminase gene HvBCAT5 is found for the first time, and the gene has obvious positive correlation with the accumulation of valine (Val), isoleucine (Ile) and leucine (Leu) of crops. The invention provides an important target gene HvBCAT5 for crop quality improvement, and has important value for increasing the content of branched chain amino acid of crops and improving dietary nutrition. The HvBCAT5 gene as well as a recombinant vector, a recombinant bacterium and a transgenic plant thereof have good application prospects in the fields of food and feed industry.
Owner:WUHAN POLYTECHNIC UNIVERSITY +1

Corynebacterium glutamicum for producing L-isoleucine and application of corynebacterium glutamicum

The invention discloses corynebacterium glutamicum for producing L-isoleucine and application of the corynebacterium glutamicum. The strain is obtained by performing ultraviolet mutagenesis and structural analogue resistance screening on corynebacterium glutamicum ATCC13869. According to the method, the L-isoleucine can be produced through direct fermentation of glucose, the yield of the L-isoleucine can reach 51.69 g / L, the conversion rate can reach 28.5%, the production efficiency is improved, meanwhile, the main raw material glucose used for fermentation is low in price and easy to obtain, the method conforms to the green food safety production concept, and industrial production of the L-isoleucine is facilitated.
Owner:ANHUI HUAHENG BIOTECH CO LTD +2

Ketoalkyd reductoisomerase mutant and genetically engineered bacterium for high yield of D-pantothenic acid

The invention provides a keto-alcohol acid reductoisomerase mutant and application of the keto-alcohol acid reductoisomerase mutant in construction of genetically engineered bacteria for high yield of D-pantothenic acid. In order to solve the technical problem that in the prior art, the yield of D-pantothenic acid synthesized through microbial fermentation is not high, semi-rational design of enzyme is adopted, and a keto-alcohol acid reductoisomerase mutant with substrate specificity is obtained and applied to construction of genetically engineered bacteria for high yield of D-pantothenic acid. According to the invention, a genetically engineered bacterium with high yield of D-pantothenic acid is constructed by utilizing the keto-alcohol acid reductoisomerase mutant through a CRISPR-Cas9 gene editing technology, so that the yield of D-pantothenic acid is increased by about 12.04%, and compared with an original strain, the valine accumulation amount in obtained fermentation liquor is almost unchanged compared with that of a control, and the yield of D-pantothenic acid is greatly improved. However, the accumulation of branched chain amino acid isoleucine is less, so that the modification of the substrate specificity of the keto-alcohol acid reductoisomerase is achieved.
Owner:ZHEJIANG UNIV OF TECH

Intestinal bacteria and serum metabolites capable of serving as type 2 diabetes biomarkers and application of intestinal bacteria and serum metabolites

The invention discloses intestinal bacteria and serum metabolites which can be used as biomarkers of type 2 diabetes mellitus (prediabetes mellitus (PDM), new diagnosis diabetes mellitus (NDDM) and diabetes mellitus (P2DM) after medication) in different disease stages, and application of the intestinal bacteria and the serum metabolites. Aiming at type 2 diabetes mellitus, predictive markers including staphylococcus aureus, escherichia coli, klebsiella pneumoniae, branched chain amino acids (leucine, valine and isoleucine) and the like, especially staphylococcus aureus of which the genome contains acetolactate synthase (ALS), are efficiently screened out. The type 2 diabetes mellitus marker disclosed by the invention can be used for early warning the illness risk of type 2 diabetes mellitus and guiding the adjustment of an intestinal microbial environment; the method can be used for indicating the correlation between the intestinal microbial environment and the type 2 diabetes mellitus and is used for assisting diagnosis; and drug action target research, accurate medication, pathogenesis research and the like are realized.
Owner:GUANGDONG GENERAL HOSPITAL

Method for producing L-leucine and L-isoleucine through fermentation

The embodiment of the invention provides a fermentation method of L-leucine and L-isoleucine. According to the method, at least one L-leucine or L-isoleucine producing strain is used for fermentation culture; according to the method, relatively cheap molasses with rich carbon and nitrogen sources is selected as materials, corn steep liquor with more impurities is abandoned, and the molasses is converted into a nutrient substance containing more carbon and nitrogen sources capable of being utilized by strains through enzymolysis; in addition, in order to control the ratio of carbon and nitrogen sources in the fermentation liquor, a more accurate material supplementing process is selected, so that the fermentation requirements of strains can be guaranteed, and the situation that the liquid nitrogen source of the fermentation liquor is too high and too low can be effectively avoided, and the purposes of increasing the yield and the sugar acid conversion rate and reducing heteroacid byproducts are achieved.
Owner:INNOBIO CORP LTD +1

Genetically engineered bacterium for producing L-isoleucine as well as construction method and application of genetically engineered bacterium

The invention belongs to the technical field of genetic engineering and enzyme engineering, and particularly relates to a genetically engineered bacterium for stably and efficiently producing L-isoleucine as well as a construction method and application of the genetically engineered bacterium. The genetically engineered bacterium takes E. coliTHRD as a host and contains an RNA (Ribonucleic Acid) polymerase beta-subunit mutant coding gene rpoBM; compared with a parent RNA polymerase beta-subunit, the RNA polymerase beta-subunit mutant has the advantage that the amino acid residue at the 618th site of the amino acid sequence is sequentially replaced with leucine from the N terminal to the C terminal. The genetically engineered bacterium disclosed by the invention can tolerate L-isoleucine and accumulate less alpha-ketobutyric acid, and has a very good industrial application prospect.
Owner:TIANJIN UNIV OF SCI & TECH

Prediction method and device for optimal branched chain amino acid proportion of daily ration of lactating sow

The invention relates to the technical field of information, and discloses a method for predicting the optimal branched chain amino acid ratio of daily ration of lactating sows, which comprises the following steps of: 1, acquiring production data and feed formula data; 2, processing the production data and the feed formula data to obtain production sample data and formula sample data; 3, performing correlation calculation on the production sample data and the formula sample data to obtain most effective features and calculate feature vectors; 4, training a preset model according to the feature vector and the formula sample data; 5, verifying the preset model, and selecting an optimal prediction model according to an evaluation result; and 6, outputting an isoleucine content prediction value, a leucine content prediction value and a valine content prediction value by the optimal prediction model. The prediction method can accurately and reliably predict the branched chain amino acid proportion of daily ration with different protein levels. Meanwhile, the invention further provides a prediction device for the optimal branched chain amino acid proportion of the daily ration of the lactating sow.
Owner:ANIMAL SCI RES INST GUANGDONG ACADEMY OF AGRI SCI

Application of pumpkin CmoKARI1 gene to promotion of Ile biosynthesis and enhancement of cucumber cold resistance

The invention relates to application of a pumpkin CmoKARI1 gene to promotion of Ile biosynthesis and enhancement of cucumber cold resistance. The CmoKARI1 gene is over-expressed in a cucumber plant, so that the low-temperature resistance of the cucumber is remarkably improved; and the low-temperature tolerance of the cucumbers is further remarkably improved by exogenous spraying of isoleucine. The new function of the CmoKARI1 gene has good application potential, a new method is provided for reducing low-temperature stress and delaying cucumber low-temperature response in production, and the CmoKARI1 gene has wide application prospects and high use value.
Owner:CHINA AGRI UNIV

P-hydroxymandelic acid synthetase, gene, mutant and application of P-hydroxymandelic acid synthetase in asymmetric synthesis of (S)-mandelic acid

The invention provides p-hydroxymandelic acid synthetase, a gene, a mutant of the p-hydroxymandelic acid synthetase and application of the p-hydroxymandelic acid synthetase in asymmetric synthesis of (S)-mandelic acid. The p-hydroxymandelic acid synthetase disclosed by the invention is derived from actinomycetes Actinokineospora auranticola, the amino acid sequence of the p-hydroxymandelic acid synthetase is as shown in SEQ ID NO.1, and a mutant of the p-hydroxymandelic acid synthetase is obtained by performing single-point mutation or multi-point combined mutation on glutamic acid at the 187th site, isoleucine at the 189th site and threonine at the 211th site of the amino acid sequence as shown in SEQ ID NO.1. The p-hydroxymandelic acid synthetase and the mutant thereof can convert phenylpyruvic acid into (S)-mandelic acid with high optical purity, have the advantages of mild reaction conditions, simplicity and convenience in operation, safety, environment friendliness and the like, and have a very good industrial application prospect.
Owner:ZHEJIANG UNIV OF TECH

Gel factor as well as preparation method and application thereof

The invention discloses a gelator and a preparation method and application thereof, the structural formula of the gelator is # imgabs0 #, R1 is a side chain group connected to an amino acid central carbon atom except an amino group, a carboxyl group and a hydrogen atom; the amino acid is selected from one of glycine, alanine, valine, leucine, isoleucine, methionine, proline, tryptophan, serine, tyrosine, cysteine, phenylalanine, asparagine, glutamine, threonine, aspartic acid, glutamic acid, lysine, arginine, histidine, selenocysteine and pyrrole lysine; the amino acid is selected from one of glycine, alanine, valine, leucine, isoleucine, methionine, proline, tryptophan, serine, tyrosine, cysteine, phenylalanine, asparagine, glutamine, threonine, aspartic acid, glutamic acid, lysine, arginine, histidine, selenocysteine and pyrrole lysine; r2 is alkyl with the carbon atom number of 16 to 19; and R3 is 9-fluorenyl methoxy carbonyl group or t-butyloxycarbonyl group. The gelator has a hydrophobic long alkyl tail chain, can spontaneously gather and assemble into a three-dimensional network structure through hydrogen bonds, pi-pi interaction and hydrophobic force, and fixes an oil phase in an oil solvent or an oil-water mixture in an effective manner to form high-strength gel.
Owner:NANJING TECH UNIV

Ketoalkyd reductoisomerase mutant and genetically engineered bacterium for high yield of D-pantothenic acid

The invention provides a keto-alcohol acid reductoisomerase mutant and application of the keto-alcohol acid reductoisomerase mutant in construction of genetically engineered bacteria for high yield of D-pantothenic acid. In order to solve the technical problem that in the prior art, the yield of D-pantothenic acid synthesized through microbial fermentation is not high, semi-rational design of enzyme is adopted, and a keto-alcohol acid reductoisomerase mutant with substrate specificity is obtained and applied to construction of genetically engineered bacteria for high yield of D-pantothenic acid. According to the invention, a genetically engineered bacterium with high yield of D-pantothenic acid is constructed by utilizing the keto-alcohol acid reductoisomerase mutant through a CRISPR-Cas9 gene editing technology, so that the yield of D-pantothenic acid is increased by about 12.04%, and compared with an original strain, the valine accumulation amount in obtained fermentation liquor is almost unchanged compared with that of a control, and the yield of D-pantothenic acid is greatly improved. However, the accumulation of branched chain amino acid isoleucine is less, so that the modification of the substrate specificity of the keto-alcohol acid reductoisomerase is achieved.
Owner:ZHEJIANG UNIV OF TECH

Nicotinamide nucleotide transhydrogenase mutant and application thereof

The invention provides a nicotinamide nucleotide transhydrogenase mutant and application thereof, valine at the 169th site of the nicotinamide nucleotide transhydrogenase mutant is designed to be mutated into isoleucine, the isoleucine is used for constructing a lysine production strain, and the new strain does not contain plasmids, does not have growth defects, does not need induction, and has the advantages of good genetic stability, high fermentation yield and the like. The lysine can be efficiently and stably produced from the beginning by taking glucose as a substrate.
Owner:TIANJIN HERUN BIOTECHNOLOGY CO LTD

Method for inhibiting generation of vomitoxin from bacillus cereus

The invention discloses a method for inhibiting production of vomitoxin from bacillus cereus, which is characterized in that isoleucine is added into a substance needing to inhibit production of vomitoxin from bacillus cereus, preferably 5-20mM of isoleucine is added. According to the present invention, the content of the toxin is detected through the liquid chromatography-mass spectrometry, and the cytotoxicity experiment verification results show that the isoleucine can significantly inhibit the synthesis of the vomitoxin of the bacillus cereus in the culture medium and the matrix, and can effectively reduce the toxic effect of the toxin on HeLa cells; the invention provides a safe and efficient biological control means which is suitable for various food systems such as starch food, dairy products, meat products and the like. Isoleucine can be used as a novel non-toxic and harmless food additive and is low in cost; the use method is simple, the output of vomitoxin can be reduced by directly adding a trace amount of isoleucine, and the food flavor is not affected.
Owner:JINAN UNIVERSITY

High-stability carbonyl reductase mutant and application thereof in synthesis of chiral alcohol

The invention discloses a high-stability carbonyl reductase mutant and application of the high-stability carbonyl reductase mutant in chiral alcohol synthesis. An amino acid sequence as shown in SEQ ID NO.2 is mutated as follows: 20th leucine is replaced by any one of lysine, threonine, aspartic acid or isoleucine, and / or 55th leucine is replaced by any one of methionine, serine, lysine or isoleucine, and / or 55th leucine is replaced by any one of methionine, serine, lysine or isoleucine. Compared with a wild type enzyme, the stability of the obtained mutant is remarkably improved, particularly, single-point mutants Mut-L20I and Mut-L55I and a combined mutant Mut-L20I-L55I show excellent relative enzyme activity, thermal stability and substrate tolerance. The mutant has high catalytic activity and stability to various chiral alcohols, has the advantages of high catalytic efficiency, high thermal stability, strong substrate tolerance, easiness in fermentation production and the like, and is suitable for industrial application of enzymatic synthesis of chiral alcohols.
Owner:ZHEJIANG UNIV OF TECH

GLP-1 analogues

The present disclosure pertains to novel Glucagon like Peptide-1 (GLP-1) (7-37) analogs having an amino acid sequence with Leu or Ile at the C-terminal. The new analogs are potent GLP-1 agonists with reduced adverse effect and improved duration of action. The present disclosure further relates to acylated derivatives of the new analogs which have further improved potency and duration of action and are suitable for oral administration. The analogs of present disclosure may be useful in treatment of diabetes and obesity.
Owner:SUN PHARMACEUTICAL INDUSTRIES LTD

Method for synthesizing rare ginsenoside Rh1 by heat-resistant UDP-glycosyl transferase

The invention discloses a UDP-glycosyl transferase mutant, and belongs to the technical field of enzyme engineering and microbial engineering. Isoleucine at the 83th site and / or phenylalanine at the 285th site of UDP-glycosyltransferase with the amino acid sequence shown as SEQ ID NO: 1 is mutated, parallel mutant screening is performed, a mutant I83A / F285M with the highest yield of generated ginsenoside Rh1 is obtained, the yield is 92% and is increased by 5.1 times compared with WT, and the mutant has a great application prospect in industrial production of ginsenoside Rh1.
Owner:JIANGNAN UNIV

Cyclic dipeptide precursor aroma component as well as preparation method and application thereof

The invention discloses a cyclic dipeptide precursor aroma component as well as a preparation method and application thereof, the high-content cyclic dipeptide precursor aroma component, especially cyclic (proline-valine) dipeptide, cyclic (proline-isoleucine) dipeptide and cyclic (proline-leucine) dipeptide, is produced through bacillus velezensis, and the cyclic (proline-valine) dipeptide, the cyclic (proline-isoleucine) dipeptide and the cyclic (proline-leucine) dipeptide are used as the precursor aroma component of the cyclic dipeptide. The cyclic dipeptide precursor aroma components and the fermentation liquor biological perfume can significantly improve the milk aroma and baking aroma of cigarettes, and enhance the corresponding aroma characteristics of the cigar tobacco leaves, so that the overall quality of the cigar tobacco leaves is improved. In addition, the cyclic dipeptide precursor aroma component generated by the bacillus velezensis and the fermentation liquor biological perfume provide a new way for improving the quality of tobacco products; the application of the components not only can enrich the sensory experience of tobacco products, but also opens up a new direction for product innovation and quality improvement in the tobacco industry.
Owner:CHINA TOBACCO SICHUAN IND CO LTD +1

A pyridoxal kinase mutant, a recombinant expression vector and a microbial cell and their applications

The present application relates to a pyridoxal kinase mutant, a recombinant expression vector and a microbial cell and their applications, and belongs to the technical field of biological catalysis. In order to solve the problem of low product concentration in existing enzyme catalysis, a pyridoxal kinase mutant is provided, the amino acid sequence is selected from the amino acid sequence shown in SEQ ID NO. 1, the lysine at position 229 is mutated to alanine, phenylalanine, methionine, arginine, threonine, histidine, serine, tyrosine, valine, leucine, isoleucine, proline, asparagine, aspartic acid or glutamic acid; the pyridoxal kinase mutant is used for catalyzing pyridoxal to synthesize pyridoxal phosphate, and a recombinant expression vector and a microbial cell can be further formed. The present application has good enzyme activity, high product conversion rate, high concentration of pyridoxal phosphate obtained, and the concentration of the product catalyzed by the wild-type pyridoxal kinase to phosphorylate pyridoxal is obviously improved.
Owner:TAIZHOU LINGFENG BIOTECHNOLOGY CO LTD

Leucine dehydrogenase mutant and application thereof

The invention discloses a leucine dehydrogenase mutant and application thereof.The mutant is obtained by replacing any one or more amino acid residues in the 36th site, the 59th site and the 109th site on the basis of a wild leucine dehydrogenase amino acid sequence, compared with the wild leucine dehydrogenase amino acid sequence, the enzyme activity of the mutant is improved by 5 times or above, the LeuDH mutant is guided into host bacteria, and the activity of the LeuDH mutant is improved by 5 times or above. The obtained recombinant bacterium is used for fermentation production of L-isoleucine, the yield of L-isoleucine reaches 30 g / L or above, compared with a wild type, the yield is remarkably improved, and powerful support is provided for fermentation production of an L-isoleucine product.
Owner:ANHUI HUAHENG BIOTECH CO LTD +2

Application of NCgl0762 protein and mutant thereof in production of L-isoleucine

The invention discloses an application of NCgl0762 protein and a mutant thereof in production of L-isoleucine, and belongs to the technical field of biology. The technical problem to be solved by the invention is how to improve the yield of L-isoleucine. The sequence of the protein disclosed by the invention is SEQ ID No. 4 or SEQ ID No. 2. The yield of the L-isoleucine can be increased by replacing the coding gene of the protein as shown in SEQ ID No.2 in starting organism cells with the coding gene of the protein as shown in SEQ ID No.4 or increasing the content or activity of the protein as shown in SEQ ID No.2 or SEQ ID No.4 in the starting organism cells.
Owner:NINGXIA EPPEN BIOTECH CO LTD

Mycobacterium tuberculosis tyrosine phenol lyase mutant and application thereof

The invention discloses a mycobacterium tuberculosis tyrosine phenol lyase mutant and application thereof, and belongs to the field of molecular biology and the technical field of biological catalysis. The mutant is obtained by mutating 384 isoleucine of tyrosine phenol lyase from mycobacterium tuberculosis into valine, and is marked as a mutant I384V. The I384V and wild type tyrosine phenol lyase have similar optimum temperature and optimum pH, but the I384V shows higher specific enzyme activity and catalytic efficiency than the wild type tyrosine phenol lyase. Compared with a wild type, the tyrosine phenol lyase mutant I384V has the advantages that the synthesis efficiency of the tyrosine phenol lyase mutant I384V on the synthesis of levodopa is improved by 38.4%, and the tyrosine phenol lyase mutant I384V has wide prospects in large-scale industrial application.
Owner:SOUTH CHINA UNIV OF TECH